CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-16). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 366 · Search date 2026-07-16 · Methodology v0.6

Pantethine,
does it really help with Reduction in LDL cholesterol and triglycerides?

30-Second Summary
C
Evidence Grade C · 52 · Safety caution
Pantethine was distinguished from pantothenic acid, and lipid values were separated from clinical events and safety.
What the
research shows
Lipid RCTs using pantethine 600-900 mg/day do exist and repeatedly signal lower LDL cholesterol and triglycerides. Many trials are old and small, however, and newer placebo-controlled data remain concentrated in the same research and trademarked-ingredient network, with small effects on laboratory markers. Pantethine is not the same ingredient as pantothenic acid, or vitamin B5.
What the
ads claim
The nutritional role of pantothenic acid should not be blended with pantethine's lipid evidence, and a small LDL change should not be presented as cardiovascular protection or drug replacement.
*

Useful facts when choosing a product

  • In Korea, pantethine is more commonly encountered in imported capsules and multi-ingredient lipid products than in domestic standalone products.
  • Clinical doses are usually 600-900 mg/day, often 300 mg two or three times daily.
  • Pantethine content cannot be read interchangeably with pantothenic acid or calcium pantothenate content.
  • People using anticoagulants, those with bleeding disorders, and patients around surgery should check safety separately.
Gap Measurement · Verdict 366 · C 52
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

A 1984 double-blind study gave 900 mg/day of pantethine to 29 participants and reported reductions in LDL cholesterol and triglycerides. A 2005 review collected 28 trials with 646 participants, but the average sample was about 22 and many studies lacked controls, limiting its confirmatory value. A 2011 triple-blind trial in 120 participants, supported by Kyowa for Pantesin, increased the dose from 600 to 900 mg/day and reported an LDL reduction of about 4%. Describing pantethine as a vitamin B5 derivative does not establish the same lipid efficacy for pantothenic acid; efficacy must not be transferred between pantethine and pantothenic acid.

02

Why this is classified as C (52)

Multiple human trials make B a candidate, but sample size, age of studies, review methods, trademarked-ingredient concentration, and restriction to lipid surrogates are substantial. The lipid precedent for small effects and manufacturer concentration yields C with 52 points.

Counterpoint. Independent large placebo-controlled trials and long-term cardiovascular outcomes would permit reassessment.

Rejudgment record. Reassessment (cross-check reflected) — Recognized the 29- and 120-participant lipid RCTs but retained C for surrogate outcomes, branded support, and the prohibition on transferring pantethine efficacy to pantothenic acid

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduction in LDL cholesterolCSmall, product-concentrated surrogate signal from RCTs
Reduction in triglyceridesCCentered on older small studies with variable effect sizes

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Gaddi et al. (1984), AtherosclerosisDouble-blind placebo-controlled trial29UnknownTotal cholesterol, LDL-C, and triglyceridesLower LDL cholesterol and triglycerides with pantethine 900 mg/dayModerate
McRae (2005), Nutrition ResearchReview of clinical literature22UnknownBlood lipidsSummarized lipid improvement, but many studies were uncontrolled and smallLow
Rumberger et al. (2011), Nutrition ResearchRandomized triple-blind placebo-controlled trial, 16 weeks120Supported by Kyowa Hakko USA; Pantesin usedLDL-C, total cholesterol, and triglyceridesSmall but significant LDL and total-cholesterol reductions at 600-900 mg/dayModerate
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-16).

Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipidemia. Atherosclerosis. 1984;50(1):73-83. PMID: 6365107. DOI: 10.1016/0021-9150(84)90009-1.
checked
McRae MP. Treatment of hyperlipoproteinemia with pantethine: a review and analysis of efficacy and tolerability. Nutr Res. 2005;25(4):319-333. DOI: 10.1016/j.nutres.2004.12.009.
checked
Rumberger JA, Napolitano J, Azumano I, Kamiya T, Evans M. Pantethine, a derivative of vitamin B5 used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. Nutr Res. 2011;31(8):608-615. PMID: 21925346. DOI: 10.1016/j.nutres.2011.08.001.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-16 · Corrections: none

Cite this verdict

Does pantethine lower LDL cholesterol and triglycerides? Evidence Grade C card
[Chamgap] Does pantethine lower LDL cholesterol and triglycerides? — Evidence Grade C·52. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/pantethine-ldl-triglycerides/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.